Publications 2024

Guldvik IJ, Ramberg H, Kristensen G, Røder A, Mills IG, Lilleby W, Taskén KA (2024)
Systemic interrogation of immune-oncology-related proteins in patients with locally advanced prostate cancer undergoing androgen deprivation and intensity-modulated radiotherapy
World J Urol, 42 (1), 95
DOI 10.1007/s00345-024-04787-8, PubMed 38386171

Publications 2022

Guldvik IJ, Braadland PR, Sivanesan S, Ramberg H, Kristensen G, Tennstedt P, Røder A, Schlomm T, Berge V, Eri LM, Lilleby W, Mills IG, Taskén KA (2022)
Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
Eur Urol Open Sci, 45, 68-75
DOI 10.1016/j.euros.2022.09.002, PubMed 36353660

Nunes-Xavier CE, Emaldi M, Guldvik IJ, Ramberg H, Taskén KA, Mælandsmo GM, Fodstad Ø, Llarena R, Pulido R, López JI (2022)
Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer
Pathol Res Pract, 241, 154243
DOI 10.1016/j.prp.2022.154243, PubMed 36481650

Publications 2021

Guldvik IJ, Ekseth L, Kishan AU, Stensvold A, Inderberg EM, Lilleby W (2021)
Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer
J Pers Med, 11 (7)
DOI 10.3390/jpm11070605, PubMed 34206815

Ramberg H, Richardsen E, de Souza GA, Rakaee M, Stensland ME, Braadland PR, Nygård S, Ögren O, Guldvik IJ, Berge V, Svindland A, Taskén KA, Andersen S (2021)
Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer
Carcinogenesis, 42 (5), 685-693
DOI 10.1093/carcin/bgab015, PubMed 33609362

Publications 2020

Guldvik IJ, Zuber V, Braadland PR, Grytli HH, Ramberg H, Lilleby W, Thiede B, Zucknick M, Saatcioglu F, Gislefoss R, Kvåle R, George A, Grönberg H, Wiklund F, Neal DE, Gnanapragasam VJ, Taskén KA, Mills IG (2020)
Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
Eur Urol Open Sci, 21, 51-60
DOI 10.1016/j.euros.2020.08.007, PubMed 34337468

Publications 2019

Braadland PR, Ramberg H, Grytli HH, Urbanucci A, Nielsen HK, Guldvik IJ, Engedal A, Ketola K, Wang W, Svindland A, Mills IG, Bjartell A, Taskén KA (2019)
The β₂-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
Mol Cancer Res, 17 (11), 2154-2168
DOI 10.1158/1541-7786.MCR-18-0605, PubMed 31395667

Publications 2018

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2018)
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer, 118 (6), e11
DOI 10.1038/bjc.2017.470, PubMed 29462127

Publications 2017

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2017)
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer, 117 (11), 1656-1664
DOI 10.1038/bjc.2017.346, PubMed 28972967

Itkonen HM, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV, Erho N, Bloch K, Davicioni E, Derua R, Waelkens E, Mohler JL, Clarke N, Swinnen JV, Keun HC, Rekvig OP, Mills IG (2017)
Lipid degradation promotes prostate cancer cell survival
Oncotarget, 8 (24), 38264-38275
DOI 10.18632/oncotarget.16123, PubMed 28415728

Publications 2015

Bollineni RC, Guldvik IJ, Grönberg H, Wiklund F, Mills IG, Thiede B (2015)
A differential protein solubility approach for the depletion of highly abundant proteins in plasma using ammonium sulfate
Analyst, 140 (24), 8109-17
DOI 10.1039/c5an01560j, PubMed 26541119

Publications 2014

Itkonen HM, Engedal N, Babaie E, Luhr M, Guldvik IJ, Minner S, Hohloch J, Tsourlakis MC, Schlomm T, Mills IG (2014)
UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation
Oncogene, 34 (28), 3744-50
DOI 10.1038/onc.2014.307, PubMed 25241896

Publications 2013

Engedal N, Torgersen ML, Guldvik IJ, Barfeld SJ, Bakula D, Sætre F, Hagen LK, Patterson JB, Proikas-Cezanne T, Seglen PO, Simonsen A, Mills IG (2013)
Modulation of intracellular calcium homeostasis blocks autophagosome formation
Autophagy, 9 (10), 1475-90
DOI 10.4161/auto.25900, PubMed 23970164

Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
Int J Cancer, 133 (6), 1497-506
DOI 10.1002/ijc.28158, PubMed 23494569

Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, Svindland A, Schlomm T, Mills IG (2013)
O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells
Cancer Res, 73 (16), 5277-87
DOI 10.1158/0008-5472.CAN-13-0549, PubMed 23720054

Publications 2011

Risberg K, Guldvik IJ, Palchaudhuri R, Xi Y, Ju J, Fodstad O, Hergenrother PJ, Andersson Y (2011)
Triphenylmethyl derivatives enhances the anticancer effect of immunotoxins
J Immunother, 34 (5), 438-47
DOI 10.1097/CJI.0b013e31821e00ae, PubMed 21577141

Publications 2008

Perander M, Aberg E, Johansen B, Dreyer B, Guldvik IJ, Outzen H, Keyse SM, Seternes OM (2008)
The Ser(186) phospho-acceptor site within ERK4 is essential for its ability to interact with and activate PRAK/MK5
Biochem J, 411 (3), 613-22
DOI 10.1042/BJ20071369, PubMed 18248330